Schroeder et al., 2013 - Google Patents
New developments in the area of factor XIIISchroeder et al., 2013
View HTML- Document ID
- 1793789931945913583
- Author
- Schroeder V
- Kohler H
- Publication year
- Publication venue
- Journal of thrombosis and haemostasis
External Links
Snippet
To cite this article: Schroeder V, Kohler HP. New developments in the area of factor XIII. J Thromb Haemost 2013; 11: 234–44. Summary Coagulation factor (F) XIII is best known for its role in fibrin stabilization and cross‐linking of antifibrinolytic proteins to the fibrin clot …
- 230000018109 developmental process 0 title abstract description 10
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schroeder et al. | New developments in the area of factor XIII | |
| Bolton‐Maggs et al. | The rare coagulation disorders–review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation | |
| Muszbek et al. | Factor XIII: a coagulation factor with multiple plasmatic and cellular functions | |
| Lagrange et al. | Alpha‐2‐macroglobulin in hemostasis and thrombosis: an underestimated old double‐edged sword | |
| Emsley et al. | Structure and function of factor XI | |
| Stockschlaeder et al. | Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis | |
| Smith et al. | Fibrin as a factor in atherogenesis | |
| Abdul et al. | Natural heterogeneity of α2-antiplasmin: functional and clinical consequences | |
| Hsieh et al. | Factor XIII deficiency | |
| Hlatky et al. | Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease | |
| Franchini et al. | Von Willebrand factor and thrombosis | |
| Gemmati et al. | Coagulation factor XIIIA (F13A1): novel perspectives in treatment and pharmacogenetics | |
| Reijerkerk et al. | No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer | |
| Soendergaard et al. | Tissue-regenerating functions of coagulation factor XIII | |
| Wind et al. | The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment | |
| Shahbazi et al. | Factor VII gene defects: review of functional studies and their clinical implications | |
| Federici | Diagnosis of inherited von Willebrand disease: a clinical perspective | |
| Franchini et al. | The role of von Willebrand factor in hemorrhagic and thrombotic disorders | |
| Sun et al. | Type VI collagen | |
| Henriksen et al. | Endotrophin, a key marker and driver for fibroinflammatory disease | |
| Mikhail et al. | An update on type 2B von Willebrand disease | |
| Castaman et al. | von Willebrand disease | |
| van Paridon et al. | Lower levels of vWF are associated with lower risk of cardiovascular disease | |
| Pimanda et al. | Control of von Willebrand factor multimer size and implications for disease | |
| Federici et al. | Advances in the genetics and treatment of von Willebrand disease |